China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totaling 3,264 shares, a decline of 64.6% from the April 15th total of 9,220 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 20,765 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Several equities research analysts have weighed in on SXTC shares. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, February 7th. Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, China SXT Pharmaceuticals currently has an average rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of China SXT Pharmaceuticals in the fourth quarter valued at approximately $36,000. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals during the 3rd quarter valued at approximately $78,000. Finally, Virtu Financial LLC grew its stake in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the period. Hedge funds and other institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Trading Up 0.6%

Shares of China SXT Pharmaceuticals stock traded up $0.01 during trading hours on Thursday, reaching $1.60. The stock had a trading volume of 11,484 shares, compared to its average volume of 218,527. The stock’s 50 day moving average is $1.86 and its 200 day moving average is $85.84. China SXT Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $1,046.99.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.